Connect with us

Hi, what are you looking for?

Tuesday, Jul 5, 2022
Mugglehead Magazine
Alternative investment news based in Vancouver, B.C.


MindMed stock surges on Nasdaq listing approval

After its stock jumped 66%, MindMed now rivals Compass Pathways as the world’s most valuable psychedelic company

MindMed stock surges on Nasdaq listing approval
MindMed stock surges on Nasdaq listing approval

MindMed (NEO: MMED) (DE: MMQ) stock jumped 66 per cent Friday after the psychedelic firm said it was approved to be listed on the Nasdaq.

The New York-based company will begin trading on the big board April 27 under the symbol MNMD, according to a statement.

“We believe this listing will increase our visibility in the marketplace, improve liquidity, broaden and diversify our shareholder base, and ultimately enhance long-term shareholder value,” CEO J.R. Rahn said in a statement.

Rahn added the listing is an important step for his company to continue its mission to develop psychedelic-inspired treatments that address substance use and mental health issues.

MindMed says it will continue being listed on the Canadian Neo Exchange, with its ticker unchanged.

The company is assembling a drug-development pipeline of innovative treatments based on psychedelic substances including psilocybin, LSD, MDMA, DMT and an ibogaine derivative, 18-MC.

The firm is backed by Shark Tank celebrity investor Kevin O’Leary and has former Canopy Growth Corp. (TSX: WEED) (Nasdaq: CGC) CEO Bruce Linton on its board of directors.

O’Leary tweeted Friday that MindMed’s multiple ongoing clinical trials is the reason why he’s invested more in the company than any other in the psychedelic space.

“When you invest in junior pharma you want as much diversity as you can,” he said.

MindMed is working with the University Hospital Basel in Switzerland to research and develop novel psychedelic therapies, compounds and dosing technologies. 

With its research partners at UHB, the company has completed 14 clinical trials on psychedelic therapies, with four ongoing.

MindMed is entering a Phase 2b clinical trial with the U.S. Food and Drug Administration at the university in hopes of developing an LSD treatment for severe anxiety.

More than 284 million people in the world suffer from anxiety, according to Institute for Health Metrics and Evaluation. More than US$4.7 billion is spent worldwide each year on anxiety drugs, and the condition causes an estimated US$1 trillion in annual lost productivity.

MindMed is slated to begin a Phase 2 trial with researchers at Maastricht University in the Netherlands to test whether low doses of acid can treat adult ADHD.

The firm became the first of more than 20 psychedelics companies to list on a public stock exchange in 2020, debuting on Canada’s NEO Exchange last March.

Read more: 2020’s top five advancements in psychedelics

Rival Compass Pathways (Nasdaq: CMPS) debuted on Nasdaq last September, making it the first psychedelics firm to list on a major U.S. stock exchange.

As MindMed shares rose to $4.42 Friday on the Neo, it moved closer to surpassing Compass as the biggest psychedelic stock by market capitalization.

MindMed has a market cap of $1.44 billion as of Friday afternoon, versus Compass’s market cap of $1.59 billion.

Top image via MindMed


Follow Mugglehead on Twitter

Like Mugglehead on Facebook

Follow Jared Gnam on Twitter

Click to comment

Leave a Reply

Your email address will not be published.

You May Also Like

Health and Safety

Science doesn't know yet, but one psychedelic researcher is chasing clues to see if it can


As more medium-to-small producers came into play this year, great weed started hitting legal shelves at fairer prices


Punishments for possession include caning and the death penalty. Despite a global trend of reform, The Fine City remains staunch in its anti-drug stance


While legal weed businesses decry enforcement of their accounts, the platform says it's keeping its all-ages community safe